创新药浪潮 | Innovative Drug Wave

GLP-1 therapies, antibody-drug conjugates, and gene editing are reshaping pharma economics. Clinical catalysts drive episodic returns, while royalty streams offer duration. SaaS business scrutiny of trial data and subscription signals filters real innovation from hype. GLP-1疗法、抗体偶联药物和基因编辑正在重塑制药经济学。临床催化剂带来阶段性回报，而特许权使用费提供久期。以SaaS创业审查试验数据和订阅信号，可以从炒作中筛选真正的创新。

医疗器械与设备 | Medtech and Devices

Robotic surgery, continuous glucose monitors, and AI diagnostics command premium valuations. Reimbursement dynamics and cloud trends dictate adoption curves. Companies with MRR-driven efficiency gain share in competitive categories. 手术机器人、连续血糖监测仪和AI诊断享有溢价估值。报销政策和云服务趋势决定采用曲线。以月经常性收入驱动效率的公司正在竞争激烈的品类中夺取份额。

数字医疗 | Digital Health

Telemedicine, remote monitoring, and AI copilots are moving from pilots to scale. Data moats and churn frameworks determine long-term winners. Partnerships with payers and providers matter more than standalone app metrics. 远程医疗、远程监测和AI助手正在从试点走向规模化。数据护城河和流失率框架决定长期赢家。与支付方和医疗服务机构的合作比独立的App指标更重要。

老龄化与长期需求 | Aging and Long-term Demand

Demographic tailwinds make healthcare a defensive growth sector. Spending on chronic care, oncology, and elder services compounds for decades. A customer acquisition-anchored allocation with scaling discipline balances innovation upside with defensive cash flows. 人口结构顺风使医疗健康成为防御性成长板块。慢性病护理、肿瘤和老年服务的支出将复合增长数十年。以获客为锚、规模化为纪律的配置，在创新上行空间与防御性现金流之间取得平衡。